Merck & Co., Inc. (MRK) last closed at $149.50, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for MRK, covered for search and blurred for visitors.
Performance
1D+1.07%
5D+1.70%
1M-0.68%
3M+14.87%
6M+32.77%
1Y+73.63%
5Y+89.84%
Financials
Over the latest four reported periods ending June 30, 2026, Merck & Co., Inc. reported revenue of $66.57 billion.
The prior window totaled $63.62 billion, so the latest window is higher than that stretch.
Operating cash flow in the latest window was $19.97 billion.
Free cash flow in the latest window was $16.06 billion.
These amounts are taken from Merck & Co., Inc.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.
A few ratios from those statements: Profitability: ROE -3.2% (0 of 100). Leverage: D/E 1.22× (51 of 100). Cash generation: FCF margin 24.1% (48 of 100). Net margin: -8.0% (0 of 100). Liquidity: Current 1.32× (66 of 100).
Finorify's notes from those filings, written October 22, 2026: Category-Defining Oncology Leadership (Keytruda). Merck maintains an exceptionally strong moat in immuno-oncology anchored by Keytruda (pembrolizumab), the world's leading PD-1 inhibitor. Its extensive array of approved indications across dozens of tumor types, combined with institutional familiarity and entrenched status in global clinical treatment guidelines, creates substantial switching costs and sustained high-margin cash flows. High-Barrier Vaccine Portfolio and Manufacturing Infrastructure. Merck possesses a leading, difficult-to-replicate franchise in preventative health, headlined by the HPV vaccine Gardasil. Vaccines require specialized biological manufacturing facilities, strict quality controls, and prolonged clinical development cycles, creating high technological and regulatory barriers to entry that protect the company from generic substitution. Global Commercial Scale and Proven R&D Engine. The company leverages multi-billion-dollar annual research and development investments, sophisticated global distribution networks, and established regulatory relationships. This scale enables Merck to systematically identify, acquire, develop, and commercialize novel therapeutics globally, while amortizing clinical development costs across broad international markets. Severe Revenue Concentration and Upcoming Keytruda Patent Cliff. A substantial portion of Merck's total revenues and operating profits relies on Keytruda. The impending expiration of Keytruda's core patent protections in the late 2020s exposes the company to aggressive biosimilar competition and steep revenue erosion if pipeline assets fail to offset the loss of exclusivity. Government Price Controls and Legislative Headwinds. Pharmaceutical pricing is under severe pressure from public payers and legislative reforms globally, most notably the Medicare drug price negotiation mechanisms introduced by the U.S. Inflation Reduction Act (IRA). Mandatory discounts and international reference pricing can materially compress gross margins on top-selling therapies. Late-Stage Clinical Trial and Pipeline Replenishment Risk. Sustaining long-term growth requires continuous successful replenishment of the pipeline through internal development and business development (M&A). Late-stage clinical trial failures, unexpected safety issues, or regulatory rejections can destroy invested capital and jeopardize future revenue streams.
Cash Flow
Margins
Valuation
P/E (TTM)
120
P/S (TTM)
5.55
EV/EBITDA
40.58
Insights
Advantage
Category-Defining Oncology Leadership (Keytruda)
Merck maintains an exceptionally strong moat in immuno-oncology anchored by Keytruda (pembrolizumab), the world's leading PD-1 inhibitor. Its extensive array of approved indications across dozens of tumor types, combined with institutional familiarity and entrenched status in global clinical treatment guidelines, creates substantial switching costs and sustained high-margin cash flows.
Advantage
High-Barrier Vaccine Portfolio and Manufacturing Infrastructure
Merck possesses a leading, difficult-to-replicate franchise in preventative health, headlined by the HPV vaccine Gardasil. Vaccines require specialized biological manufacturing facilities, strict quality controls, and prolonged clinical development cycles, creating high technological and regulatory barriers to entry that protect the company from generic substitution.
Advantage
Global Commercial Scale and Proven R&D Engine
The company leverages multi-billion-dollar annual research and development investments, sophisticated global distribution networks, and established regulatory relationships. This scale enables Merck to systematically identify, acquire, develop, and commercialize novel therapeutics globally, while amortizing clinical development costs across broad international markets.
Risk
Severe Revenue Concentration and Upcoming Keytruda Patent Cliff
A substantial portion of Merck's total revenues and operating profits relies on Keytruda. The impending expiration of Keytruda's core patent protections in the late 2020s exposes the company to aggressive biosimilar competition and steep revenue erosion if pipeline assets fail to offset the loss of exclusivity.
Risk
Government Price Controls and Legislative Headwinds
Pharmaceutical pricing is under severe pressure from public payers and legislative reforms globally, most notably the Medicare drug price negotiation mechanisms introduced by the U.S. Inflation Reduction Act (IRA). Mandatory discounts and international reference pricing can materially compress gross margins on top-selling therapies.
Risk
Late-Stage Clinical Trial and Pipeline Replenishment Risk
Sustaining long-term growth requires continuous successful replenishment of the pipeline through internal development and business development (M&A). Late-stage clinical trial failures, unexpected safety issues, or regulatory rejections can destroy invested capital and jeopardize future revenue streams.
Read the live analysis in Finorify
Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.